- Home
- GVA vs AXSM Comparison
GVA vs AXSM Comparison
Compare GVA & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GVA
- AXSM
- Stock Information
- Founded
- GVA 1922
- AXSM 2012
- Country
- GVA United States
- AXSM United States
- Employees
- GVA N/A
- AXSM N/A
- Industry
- GVA Military/Government/Technical
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- GVA Industrials
- AXSM Health Care
- Exchange
- GVA Nasdaq
- AXSM Nasdaq
- Market Cap
- GVA 3.8B
- AXSM 4.2B
- IPO Year
- GVA 1990
- AXSM 2015
- Fundamental
- Price
- GVA $82.17
- AXSM $137.75
- Analyst Decision
- GVA Hold
- AXSM Strong Buy
- Analyst Count
- GVA 2
- AXSM 14
- Target Price
- GVA $67.00
- AXSM $158.93
- AVG Volume (30 Days)
- GVA 638.5K
- AXSM 1.1M
- Earning Date
- GVA 02-13-2025
- AXSM 02-18-2025
- Dividend Yield
- GVA 0.63%
- AXSM N/A
- EPS Growth
- GVA 169.33
- AXSM N/A
- EPS
- GVA 2.62
- AXSM N/A
- Revenue
- GVA $4,007,574,000.00
- AXSM $385,693,000.00
- Revenue This Year
- GVA $8.05
- AXSM $45.18
- Revenue Next Year
- GVA $6.10
- AXSM $65.22
- P/E Ratio
- GVA $31.32
- AXSM N/A
- Revenue Growth
- GVA 14.20
- AXSM 42.53
- 52 Week Low
- GVA $48.52
- AXSM $64.11
- 52 Week High
- GVA $105.20
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- GVA 32.31
- AXSM 74.55
- Support Level
- GVA $83.65
- AXSM $124.04
- Resistance Level
- GVA $88.30
- AXSM $130.52
- Average True Range (ATR)
- GVA 2.62
- AXSM 5.78
- MACD
- GVA -0.38
- AXSM 1.11
- Stochastic Oscillator
- GVA 6.82
- AXSM 96.07
About GVA Granite Construction Incorporated
Granite Construction Inc engages in the construction and development of various infrastructure projects on behalf of public and private clients in the United States. It focuses on heavy civil infrastructure projects, including roads, highways, transit facilities, airports, bridges and other infrastructure projects. In addition, the company performs site preparation and infrastructure services for residential development, energy development, and other facilities. The majority of revenue is derived from the company's Construction operating segment, with the remainder derived from its Materials segment.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.